Prochymal®, mesenchymal stem cells for treatment of type 1 diabetes mellitus

Prochymal®, an intravenously administered formulation of mesenchymal stem cells (MSCs), is being developed for the protection of pancreatic islet cells in patients with type 1 diabetes. This Phase 2 study objective was to evaluate the efficacy and safety of Prochymal® in patients recently diagnosed with type 1 diabetes mellitus (T1DM).